中国白癜风患者临床标志物与疾病进展的关联
这项前瞻性队列研究纳入425例中国白癜风患者,随访12个月,评估三联征、彩纸样脱色和Koebner现象与疾病活动性、严重程度及预后的关系。结果显示,至少有一个临床标志物的患者疾病活动期比例更高、快速进展比例更高,且VASI评分改善更小。
要点
- 临床标志物存在与白癜风活动期和快速进展相关。
- 有临床标志物者VASI评分改善更小,预后更差。
- 多个临床标志物可能需更积极治疗。
核心结论
- 白癜风患者存在临床标志物可能关联更差预后和快速疾病进展。
- 有多个临床标志物的患者可能需要更强化治疗。
研究设计与样本
- 前瞻性队列研究,纳入2016年9月1日至2019年5月13日复旦大学附属华山医院门诊425例白癜风患者。
主要发现
- 至少1个临床标志物组首次就诊时活动期比例为97.5%(196/201),无标志物组为71.0%(159/224),P < .001。
- 至少1个临床标志物组3个月随访时活动期比例为45.3%(91/201),无标志物组为23.2%(52/224),P < .001。
- 至少1个临床标志物组1个月随访时快速进展比例为70.6%(142/201),无标志物组为26.8%(60/224),P < .001。
- 至少1个临床标志物组3个月随访时快速进展比例为31.3%(63/201),无标志物组为4.0%(9/224),P < .001。
- VASI评分改善(均值[SD])在有至少1个临床标志物组6个月为0.14(0.12),无标志物组为0.23(0.21),P = .02;9个月为0.29(0.19) vs 0.44(0.25),P = .03;12个月为0.47(0.21) vs 0.63(0.23),P = .03。
关键数值与推荐
- 活动期白癜风定义为白癜风欧洲工作组扩散评分至少1分或Wood灯下出现边缘不清的色素减退性皮损。
临床怎么用
- 临床可依据三联征、彩纸样脱色和Koebner现象评估白癜风活动性和进展风险。
- 对存在临床标志物尤其是多个标志物的患者,考虑更密切随访和更积极治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is necessary to determine whether established clinical markers of vitiligo are associated with disease progression, severity, and patient prognosis. OBJECTIVE: To evaluate the utility of trichrome sign, confetti-like depigmentation, and Koebner phenomenon in assessing disease progression, severity, and prognosis in patients with vitiligo. DESIGN, SETTING, AND PARTICIPANTS: In this prospective cohort study, 425 patients with vitiligo were recruited from the outpatient department of Huashan Hospital, Fudan University in Shanghai, China, from September 1, 2016, to May 13, 2019. MAIN OUTCOMES AND MEASURES: Disease progression, severity, and prognosis during a 12-month period. The active stage of vitiligo was defined as Vitiligo European Task Force spreading score of at least 1 or more lesions appearing as hypomelanotic with poorly defined borders using a Wood light. Progression was assessed using the Vitiligo Area Scoring Index (VASI) and serum CXCL10 level measurement. RESULTS: Of the 458 enrolled patients, 425 (235 female [55.3%]; mean [SD] age, 30.9 [10.2] years) completed the 12-month follow-up. Of the 425 patients (224 with no clinical marker and 201 with at least 1 clinical marker) included in this analysis, the proportion in the active stage of the disease was significantly higher in the cohort with at least 1 clinical marker compared with the cohort without any clinical marker at the first visit (196 of 201 [97.5%] vs 159 of 224 [71.0%]; P < .001) and at 3-month follow up (91 of 201 [45.3%] vs 52 of 224 [23.2%]; P < .001). The proportion of patients with rapid disease progression was also higher in the group with at least 1 clinical marker at 1-month follow-up (142 of 201 [70.6%] vs 60 of 224 [26.8%]; P < .001) and 3-month follow-up (63 of 201 [31.3%] vs 9 of 224 [4.0%]; P < .001). The improvement in VASI score (SD) was significantly smaller among patients with at least 1 clinical marker compared with those without any clinical marker at 6 months (mean [SD], 0.14 [0.12] vs 0.23 [0.21]; P = .02), at 9 months (mean [SD], 0.29 [0.19] vs 0.44 [0.25]; P = .03), and at 12 months (mean [SD], 0.47 [0.21] vs 0.63 [0.23]; P = .03). CONCLUSIONS AND RELEVANCE: The presence of a clinical marker in patients with vitiligo may be associated with worse prognosis and rapid disease progression. Patients with multiple clinical markers may require more intensive treatment.
引用
- Zhang L, Chen S, Kang Y, et al. Association of Clinical Markers With Disease Progression in Patients With Vitiligo From China. JAMA Dermatol. 2020. PMID: 31968061. doi:10.1001/jamadermatol.2019.4483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。